differentiated thyroid cancer
Oncology · 2015–2018
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lenvatinib Locally advanced or metastatic differentiated thyroid cancer that is refractory to radioactive iodine, in patients for whom surgery is inappropriate and… | Jul 2018 | Recommended with restriction | none received |
| sorafenib Treatment of locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer (RAI-R DTC). | Mar 2015 | Deferred | 2 individuals Rare Cancer Australia |
Who spoke
Rare Cancer Australia
What the PBS pays
$32M in government benefit over 2024–25, across 8,313 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| lenvatinib | $31.4M |
| sorafenib | $0.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 1 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| cabozantinibCabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | not recommended | 2023-11 |
| lenvatinib and sorafenibLenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | recommended restricted | 2018-08 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.